3 results
Approved WMORecruitment stopped
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients (no prior exposure to factor products or any blood products) of less than 6 years of age.
Approved WMOWill not start
Evaluate whether FVIII/VWF concentrates successfully induce immune tolerance in patients who have already experienced and failed immune tolerance induction with VWF-free FVIII concentrates.
Approved WMORecruiting
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)